{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T09:27:56Z","timestamp":1763458076551,"version":"3.44.0"},"reference-count":5,"publisher":"SMC Media","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Cryoglobulinaemia is defined as the presence of cryoglobulins in the serum, which are immunoglobulins that reversibly precipitate and form a gel when the temperature is &lt;37\u00baC. Autoimmune diseases such as Sjogren\u2019s syndrome, systemic lupus erythematosus and rheumatoid arthritis could be associated with mixed cryoglobulinaemia vasculitis (MCV). The treatment of MCV generally consists of glucocorticoids, cytotoxic agents such as cyclophosphamide, plasmapheresis or anti-CD20 monoclonal antibodies including rituximab. Here, we present a case of a 60-year-old woman who developed type II MCV in the context of overlap autoimmune disease and who has been treated with a new anti-CD20 agent, obinutuzumab.<\/jats:p>","DOI":"10.12890\/2021_003019","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T03:17:25Z","timestamp":1637551045000},"source":"Crossref","is-referenced-by-count":2,"title":["Mixed Cryoglobulinaemia Vasculitis Treated with Obinutuzumab in a Patient Allergic to Rituximab"],"prefix":"10.12890","volume":"8","author":[{"given":"Margarida","family":"Gaudencio","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hospital Distrital da Figueira da Foz, EPE, Figueira da Foz, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catarina","family":"Parente","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hospital Barreiro-Montijo, Lisboa, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Catarina","family":"Lameiras","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hospital Fernando Fonseca, Lisboa, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ant\u00f3nio","family":"Marinho","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Centro Hospitalar do Porto, Porto, Portugal; Faculty of Medicine, Instituto de Ci\u00eancias Biom\u00e9dicas Abel Salazar, Porto, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10397","published-online":{"date-parts":[[2021,11,22]]},"reference":[{"key":"10.12890\/2021_003019_ref1","doi-asserted-by":"crossref","unstructured":"<li>Roccatello D, Saadoun D, Ramos-Casals M, Tzioufas AG, Fervenza FC, Cacoub P, et al. Cryoglobulinaemia. <em>Nat Rev Dis Primers<\/em> 2018;<strong>4<\/strong>(1):11. <\/li>","DOI":"10.1038\/s41572-018-0009-4"},{"key":"10.12890\/2021_003019_ref2","doi-asserted-by":"crossref","unstructured":"<li>Crickx E, Weill JC, Reynaud CA, Mahevas M. Anti-CD20-mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives. <em>Kidney Int<\/em> 2020;<strong>97<\/strong>:885\u2013893. <\/li>","DOI":"10.1016\/j.kint.2019.12.025"},{"key":"10.12890\/2021_003019_ref3","doi-asserted-by":"crossref","unstructured":"<li>Robak T, Robak E. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. <em>BioDrugs<\/em> 2011;<strong>25<\/strong>:13\u201325. <\/li>","DOI":"10.2165\/11539590-000000000-00000"},{"key":"10.12890\/2021_003019_ref4","doi-asserted-by":"crossref","unstructured":"<li>Tobinai K, Klein C, Oya N, Fingerle-Rowson G. A review of obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with B-cell malignancies. <em>Adv Ther<\/em> 2017;<strong>34<\/strong>:324\u2013356.<\/li>","DOI":"10.1007\/s12325-016-0451-1"},{"key":"10.12890\/2021_003019_ref5","doi-asserted-by":"crossref","unstructured":"<li>Barnas J, Looney R, Anolik J. B cell targeted therapies in autoimmune disease. <em>Curr Opin Immunol<\/em> 2019;<strong>61<\/strong>:92\u201399.<\/li>","DOI":"10.1016\/j.coi.2019.09.004"}],"container-title":["European Journal of Case Reports in Internal Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/download\/3019\/2898","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/download\/3019\/2899","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/download\/3019\/2899","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T12:18:29Z","timestamp":1755865109000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/view\/3019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,22]]},"references-count":5,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.12890\/2021_003019","relation":{"has-manifestation":[{"id-type":"other","id":"1-79-3019-g2898","asserted-by":"subject"},{"id-type":"other","id":"1-79-3019-g2899","asserted-by":"subject"}],"is-part-of":[{"id-type":"other","id":"1-79","asserted-by":"subject"}]},"ISSN":["2284-2594"],"issn-type":[{"type":"electronic","value":"2284-2594"}],"subject":[],"published":{"date-parts":[[2021,11,22]]},"article-number":"10"}}